March 23, 2020 Go or no go? Covid-19 upstages US regulatory decisions A Vantage analysis of FDA decisions expected in the next month and how the ongoing Covid-19 pandemic could affect these.
December 02, 2019 Go or no go? Vascepa’s finale and Allergan's pain relief Amarin’s Vascepa and Allergan’s migraine project ubrogepant are the high-profile pending FDA approval decisions as the sector heads into the last month of the year.
